Beijing Tongren Hospital
Clinical trials sponsored by Beijing Tongren Hospital, explained in plain language.
-
New drug duo takes on hard-to-treat head and neck cancer
Disease control Recruiting nowThis early-stage study tests two drugs (finotonlimab and stapokibart) together in 10 adults with head and neck cancer that has come back or spread. All participants have already tried standard treatments. The main goals are to see if the combination is safe and whether it shrinks…
Phase: PHASE1 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New cocktail of drugs shows promise for deadly brain cancer
Disease control Recruiting nowThis phase 2 trial tests a combination of three drugs—pomalidomide, tislelizumab, and selinexor—in 43 people with relapsed or refractory primary central nervous system lymphoma. The goal is to see if this cocktail can shrink tumors and improve survival. All participants receive t…
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for deadly lymphoma combo: drug cocktail targets both cancer and immune chaos
Disease control Recruiting nowThis trial tests a new combination of drugs (MEPL-G) for people with a rare and aggressive lymphoma (NK/T-cell) that has triggered a life-threatening immune overreaction called HLH. The goal is to control both the cancer and the dangerous inflammation quickly. About 25 adults wil…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail aims to beat tough lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether adding the drug zanubrutinib to a standard chemotherapy regimen (Pola-R-CHP) can improve outcomes for people with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who have high-risk features. About 50 participants will receive the combination…
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for lymphoma patients: targeted therapy trial launches
Disease control Recruiting nowThis study tests a drug called orelabrutinib, alone or with another drug (CD20 antibody), in 88 people with untreated marginal zone lymphoma. The goal is to see how well the treatment shrinks or controls the cancer. Participants take the drug daily for 6 cycles, and those with mo…
Phase: PHASE4 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New glasses may slow kids' worsening eyesight
Disease control Recruiting nowThis study tests two types of special glasses (D.S.D.O. lenses) designed to slow the progression of nearsightedness (myopia) in children aged 6 to 14. About 120 children will wear the glasses daily for one year and have regular eye checkups. The goal is to see if these lenses can…
Phase: NA • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New shot could tame severe hay fever symptoms
Symptom relief Recruiting nowThis study tests a new antibody drug for people whose seasonal allergies (hay fever) are not controlled by standard treatments. The drug targets a protein involved in allergic inflammation. About 120 adults will receive either the antibody or a placebo, and researchers will measu…
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Your eyes could reveal hidden clues about heart and blood vessel health
Knowledge-focused Recruiting nowThis study looks at how high blood pressure, diabetes, and high cholesterol affect the tiny blood vessels in the back of the eye. Researchers will use a special, non-invasive camera to take detailed images of the retina and track changes over five years. The goal is to see if eye…
Sponsor: Beijing Tongren Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC